ASND logo

ASND Ascendis Pharma A/S

NASDAQ Global Select · Biotechnology · Healthcare

$270.33
-0.86 (-0.32%)

Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. Thes…

Market Cap: $17.73Bascendispharma.com

Price

No data yet.

Social Signal Score

58
5d
—
30d
70
1 mentions
—
60d
50
3 mentions
—
90d
53
7 mentions
—
news: 7

Analyst Ratings

26 analysts
Buyconsensus
Strong Buy 0Buy 24Hold 2Sell 0Strong Sell 0
Avg price target$310.69+14.9%
Low $268Median $319High $352
Current Consensus

Revenue

$367.46M+35131.19%
$18.0K$122.50M$244.98M$367.46M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-3.35
$-4.03–$-1.78
12 analysts
FY2026
$15.03
$13.10–$16.89
11 analysts
FY2027
$9.84-34% YoY
$5.23–$12.58
12 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Jan Moller Mikkelsen
Sector
Healthcare
Industry
Biotechnology
Employees
1,189
Beta
0.40
Country
DK
Piotroski score
6 / 9 (Middling)
Altman Z-score
10.76
ascendispharma.com